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this method is capable of identifying novel polymorphisms as well
as recognizing polymorphisms that have already been identiﬁed as
informative for distinguishing the various alleles. When fully de-
veloped the method will be two-tiered i.e., capable of resolving
KIR genotypes with locus-speciﬁcity or at an allele-speciﬁc level of
resolution. We present data from previously characterized control
DNA samples and transplant samples using this novel typing
method to demonstrate that the method is capable of accurately
deﬁning KIR genotypes.
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REDUCED INTENSITY PERIPHERAL BLOOD STEM CELL TRANSPLANT
FROM MATCHED RELATED AND UNRELATED DONORS FOR POOR RISK
HEMATOLOGICAL MALIGNANCY
Rossetti, J.M., Lieb, J.V., Shadduck, R.K., Gryn, J.F., Lister, J. West-
ern Pennsylvania Cancer Institute, Pittsburgh, PA.
46 patients with advanced, poor risk hematological malignancy
underwent conditioning with Fludarabine 120 mg/m2, Melphalan
140-180 mg/m2 and Ethyol 910 mg/m2 (FME) followed by periph-
eral blood stem cell transplant (PBSCT) from matched sibling
(sib-allo) (n  25) or matched unrelated donor (MUD) (n  21).
Average age was 46 years (range 19-65). Graft versus host disease
(GVHD) prophylaxis consisted of mycophenolate mofetil 1 gram
q12h through day 35 and dosage adjusted tacrolimus to a target
trough serum level of 5-15 ng/ml through day 90. At 30 days (n 
46) transplant related mortality (TRM) was11%, overall survival
(OS) was 89%, and relapse mortality (RM) was 0%. At 100 days
(n 45) TRM was 40%, OS was 51%, and RM was 9%. The most
frequent causes of death at day 100 were acute GVHD, disease
relapse, and adult respiratory distress syndrome. White blood cell
engraftment was achieved in 98% of patients in an average of 13
days (range 9-21). This engraftment was achieved and maintained
without the use of donor lymphocyte infusion (DLI). One patient
died at day 24 without engrafment. Platelet engraftment was
achieved in 80% of patients in an average of 18 days. In one patient
the platelet count never declined below 20 k/L. Eight patients
died prior to platelet engraftment. All evaluable patients showed
95% donor marrow cells at 100 days after transplant. Acute
GVHD incidence for patients not receiving DLI and alive more
than 30 days after transplant was 56% (grade 2  1, 3  17, 4 
4). For patients more than one year after transplant (n  33) the
OS was 30% (sib-allo  37%, MUD  21%) and disease free
survival was 18% (sib-allo  21%, MUD  14%).
In this aged, heavily pretreated, poor risk group of patients,
reduced intensity PBSCT using FME can yield short-term sur-
vival. This regimen provided rapid and durable engraftment with
full donor hematopoiesis in a majority of patients without the need
for DLI. In an effort to reduce the incidence of acute GVHD and
hopefully TRM, we have added thymoglobulin to the conditioning
regimen at 2 mg/kg/day to be given on days -2, -1, and 0. The
impact on OS, DFS, and chronic GVHD remains to be deter-
mined.
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INTRAVENOUS BUSULFAN VERSUS MELPHALAN-BASED LOW INTEN-
SITY CONDITIONING PRIOR TO ALLOGENEIC STEM-CELL TRANSPLAN-
TATION: LOWER TRM AND A MORE FAVORABLE TOXICITY PROFILE
Shimoni, A.1, Hardan, I.1, Yeshurun, M.1, Avigdor, A.1, Papatrypho-
nos, A.2, Tsolakis, F.I.3, Nagler, A.1 1. Chaim Sheba Medical Center,
Tel-Hashomer, Israel; 2. Archbishop Makarios III, Nicosia, Cyprus; 3.
Limassol General Hospital, Limassol, Cyprus.
Low intensity conditioning (LIC) regimens have been designed
to reduce the toxicity associated with allogeneic stem-cell trans-
plantation (SCT) and to allow SCT in elderly, heavily pretreated
and medically inﬁrm patients. However, the toxicity associated
with some of these regimens is still substantial and it is currently
unknown whether any of the regimens has advantage over the
others. We compared the toxicity and 1-year treatment related
mortality (TRM) following two LIC regimens: ﬂudarabine and
intravenous busulfan (FivBu) (total intravenous Busulfan dose 6.4
mg/kg) and ﬂudarabine and melphalan (FM) (total melphalan dose,
100-140 mg/m2). Fludarabine dose was 125-150 mg/m2 in both
regimens. Ninety-ﬁve patients with various hematologic malignan-
cies (52% chemo-refractory) not eligible for standard condition-
ing, were included in the study. Forty-nine patients (52%) had a
prior autologous SCT. The median age was 52 years (range, 20-66
years). Fifty-three patients had FM and 42 had FivBu. The donor
was an HLA-matched sibling (n  63) or a matched unrelated
donor (n  32). With a median follow-up of 10 months (range,
1-38) 55 patients are alive. Twenty patients (21%) have died due to
TRM. TRM occurred in 4 patients (10%) and 16 patients (30%)
within 1 year following FivBu and FM, respectively. The estimated
Kaplan-Meyer TRM risk was 11  5% and 33  7%, respectively
(p  0.02). The univariant analysis also identiﬁed a prior autolo-
gous SCT within 1 year of the current SCT (p  0.02) and
diagnosis of lymphoma (p  0.05) as risk factors for TRM. Age,
donor source, and chemo-sensitivity were not signiﬁcant. When
these variables were included in a multivariable Cox regression
model the hazard ratios for TRM for patients conditioned with
FM, patients with a prior SCT and patients with lymphoma were
3.2 (1.1-9.6; p 0.04), 2.5 (1.0-6.0; p 0.05) and 2.2 (0.9-5.3; p
0.08), respectively. Severe mucositis and organ dysfunction were
more common after FM, while neutropenia duration was shorter
after FivBu. In conclusion, FivBu has a more favorable toxicity
proﬁle and relatively low TRM as RIC for SCT and may prove to
be the preferred LIC regimen. Disease-speciﬁc studies are required
to assess the impact of different conditioning regimens on relapse
rate, and whether reduction of TRM will translate to better dis-
ease-free survival.
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CYCLOPHOSPHAMIDE, TOTAL BODY IRRADIATION (TBI) AND MAB-
CAMPATH (ALEMTUZUMAB) AS CONDITIONING FOR VOLUNTARY UN-
RELATED DONOR (VUD) HAEMOPOIETIC STEM CELL TRANSPLANTS
(HSCT): THE SCOTTISH EXPERIENCE
Bhandari, S., Walker, M., Holyoake, T., Franklin, I.M., McQuaker,
G., Parker, A.N. Glasgow Royal Inﬁrmary, Glasgow, Scotland, United
Kingdom.
Scotland has a population of approximately 5 million people and
supports a single VUD allograft centre based in Glasgow. We
adopted a conditioning regime consisting of 60 mg/kg cyclophos-
phamide D-6 to D-5, TBI 1440 Gy in 8 fractions D-4 to 0 and
Mabcampath 10 mg D-5 to -1 in year 2000. Data was collected
retrospectively in 9/03 for the 21 VUD HSCT patients (pts)
conditioned with this regime between 4/00 and 4/03. 11 males and
10 females were transplanted for the following diagnoses; 12 AML
(7CR1, 5CR2), 4 ALL (2CR1, 2CR2), 4 MDS and 1 NHL (CR2).
The median age was 31 years (range 17-50). Molecular tissue
typing carried out at the A, B, Cw, DRB1 and DQ loci matched at
all 10 loci in 17 pts. 3 pts mismatched at class 2 (2DRB1;1DQ) and
1 mismatched at 2 loci (DRB1 and Cw). 12 pts received unmodiﬁed
bone marrow median dose 3.2x108 mononuclear cells/kg (range 1
to 6.7x 108) and 9 had peripheral blood stem cells median dose
7x106 CD34/kg (range 1.4 to 12x106). All received short course
methotrexate and cyclosporine as graft versus host disease (GvHD)
prophylaxis, which was tapered from D100 if there was no acute
GvHD. Median follow up was 647 days (range 170 to 1233 days).
The median time to neutrophil engraftment 0.5x109/l was 17 days
(range 13 to 29 days) and platelets 20x 109/l was 17 days (range
11 to 32 days). There were no graft failures. Acute grade II-IV
GvHD occurred in 5 pts (23.8%) with grade II in 3 (14.3%) and
grade III in 2 (9.5%). No grade IV acute GVHD was seen. Of the
5 acute GvHD pts, 1 died of disease relapse, 2 died of post
transplant lymphoproliferative disorder (PTLD), 1 developed
chronic extensive GvHD (grade III pt) and 1 had complete reso-
lution of acute GvHD. Relapse occurred in 5 pts (24%). The D100
transplant related mortality (TRM) was 14.3% and at 3.4 years the
overall survival was 48% and TRMwas 33%. There were 11 (52%)
deaths in total, 4 due to disease relapse, 4 infection, 2 PTLD and
1 haemorrhage.
The incidence of grade II-IV acute GVHD is low supporting the
use of Mabcampath as an effective anti-GvHD agent. The two
cases of PTLD were surprising given that Mabcampath depletes
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both T and B cells in the recipient, although one of them (grade III
acute GvHD pt) had received anti-lymphocyte globulin for acute
GvHD treatment. Our experience supports the results obtained
with the same regime reported by the Nottingham team. The
regime is well tolerated with sustained engraftment, acceptable
toxicity, relapse risk and TRM.
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FLUDARABIN AND BUSULFAN AS A CONDITIONING REGIMEN FOR
ALLOGENEIC PERIPHERAL BLOOD STEM CELLS TRANSPLANTATION IN
LEUKEMIC PATIENTS
Ghavamzadeh, A., Iravani, M., Evazi, M., Shamshiri, A., Mousavi,
A., Bahar, B., Gholibeikian, S., Chardoli, B., Jahani, M. Hematology-
Oncology & BMT Research Center, Tehran, Islamic Republic of Iran.
We evaluated Fludarabin (40 mg/m2 on days -6 to -2) and
Busulfan (4 mg/kg/day on days -5 to -2) as a new conditioning
regimen for allogeneic peripheral blood stem cells transplantation
in standard-risk leukemic patients. Enrolled were 29 reportable
patients (9 ALL, 12 AML and 8 CML; F  13 M  16) from 52
transplanted patients with matched related donor. The median
patient age was 29 (range, 15-42). Cyclosporine was used as a
prophylactic agent for GVHD (3mg/kg IV till 4, 10 mg/kg oral
from day 5). The median follow-up was 123 days (range, 77-217
days). About 89.3% and 27.6% of the patients developed mucositis
(min  3, max  15) and hepatic toxicity (min  7, max  46)
respectively which resolved with conservative therapy. There was
no cardiac toxicity (except one patient with mild pericardial effu-
sion). The median of highest serum creatinin level during hospi-
talization and synchronous cyclosporine level were 1.6 mg/dl
(range, 1.1-3.6; 28.6% with Cr  2) and 275 ng/ml (range, 9-814).
One patient experienced hemorrhagic cystitis (infection was ruled
out). 17.2% experienced moderate to severe headache. 34.5% and
10% of the patients showed grade 1, 2 and grade 3 Acute GVHD
(there was no grade 4 Acute GVHD). Two ALL patients relapsed
on days95 and100 and one died (unrelated to regimen). In day
38, 92.3% of the patients had more than 90% whole blood
engraftment (with STR-PCR technique; median, 100%; range,
75-100).
It could be beneﬁcial to use Fludarabin versus Cyclophospha-
mide in standard conditioning regimen for leukemic patients be-
cause of reduced toxicity, low incidence of acute GVHD and
facilitated donor engraftment.
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CORRELATION OF PRE-HEMATOPOIETIC CELL TRANSPLANT (HCT)
PRO-INFLAMMATORY CYTOKINES IN BRONCHIOALVEOLAR LAVAGE
(BAL) FLUID WITH PULMONARY COMPLICATIONS FOLLOWING HCT IN
PATIENTS WITH INHERITED METABOLIC STORAGE DISORDERS
(IMSDS)
Kharbanda, S., Peters, C., Blazar, B.R., Milla, C.E., Haddad, I.Y.,
Cornﬁeld, D.N., Abel, S.L., Steiner, M., Grewal, S.S., Ramsay,
N.K.C., Panoskaltsis-Mortari, A., Baker, S. University of Minnesota,
Minneapolis, MN.
Introduction: HCT is recommended in selected patients with
inherited lysosomal and peroxisomal storage disorders including
the mucopolysaccharidoses (Hurler and Maroteaux-Lamy syn-
drome) and the leukodystrophies (adrenoleukodytsrophy [ALD],
globoid cell leukodystrophy [GLD], metachromatic leukodystro-
phy [MLD]). However, patients with IMSDs undergoing HCT are
at a higher risk of life threatening pulmonary complications such as
diffuse alveolar hemorrhage (DAH) and idiopathic pneumonia
syndrome (IPS). The etiology and risk factors for these complica-
tions are unknown. We obtained BAL ﬂuid from IMSD patients
prior to transplant and analyzed it for the levels of various pro-
inﬂammatory cytokines in order to investigate their correlation
with the development of subsequent pulmonary complications.
Methods: Between August 1999 and March 2003, 60 BAL speci-
mens were obtained from 48 IMSD patients pre-HCT (Hurler
-21, ALD-16, MLD-6, Maroteaux-Lamy-2, GLD-1, Mucolipido-
sis II-1, and -mannosidosis-1). BAL ﬂuid was analyzed for various
pro-inﬂammatory cytokines including IL-1, TNF-, IFN-	,
IL-2, IL-6, as well as chemokines including Migration Inhibitory
Factor (MIP-1) and Monocyte Chemotactic Protein (MCP). Re-
sults: In this series, the overall incidence of pulmonary complica-
tions was 54% (26/48), this included 25% (12/48) infectious com-
plications and 29% (14/48) non-infectious complications (mainly
DAH and IPS)). Evaluable pre-HCT BAL cytokine data was avail-
able on 35 patients. These included 5 patients in the infectious, 8
in the non-infectious and 22 in the no complications groups re-
spectively. There were trends towards higher levels of pre-HCT
IL-1 and IL-6 in patients who subsequently developed non-
infectious complications(P  NS, however) Conclusions: Our
study conﬁrms a high incidence of pulmonary complications in the
early post transplant period in patients with IMSDs. Patients with
mucopolysacchridoses are at a higher risk of developing non-
infectious complications like DAH as compared to patients with
other IMSDs. In this study sample of 48 patients, the levels of
pro-inﬂammatory cytokines were not found to be correlated with
this increased risk; however, there were deﬁnite trends towards
higher levels of IL-1 and IL-6 in the BAL ﬂuids; this may be
attributable to the small numbers of patients in the study. Further
studies are needed to conﬁrm the role of pro-inﬂammatory cyto-
kines in the pathogenesis of pulmonary complications in patients
with IMSDs.
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GRAFT-VERSUS-LYMPHOMA EFFECT YIELDS HIGH PERCENTAGE OF
DURABLE COMPLETE REMISSION IN HIGH-RISK PATIENTS FOLLOW-
ING MINI-TRANSPLANTATION WITH MAP (MITOXANTRONE, ARA-C,
AND PENTOSTATIN) REGIMEN
Liu, D., Seiter, K., Chiao, J.W., Qureshi, A., Ahmed, T. New York
Medical College and Arlin Cancer Institiute, Valhalla, NY.
We have developed a novel Non-myeloablative Stem Cell Trans-
plantation (NST) conditioning regimen (MAP regimen) using Mi-
toxantrone (40mg/m2 day-6), AraC (2 gm/m2 on day -6, -5, and
-4), and Pentostatin (5 mg/m2 on day -6 and -5, 3 mg/m2 on day
-4) for patients with hematological malignancies. Equine ATG at
15 mg/kg/day x 4 (day -5 to -2) is added for unrelated and mis-
matched transplantation. 18 patients (15 related, 4 unrelated) with
lymphoma are evaluable. Among them were 13 NHL, 5 HD. 14/18
patients had failed prior autologous stem cell transplantation
(Auto-SCT). The rest were either in advanced relapse or had poor
prognostic factors.
Median time to ANC  500 was 12 days, and to Platelets  20
was 11 days. Full donor Chimerism is achieved at 3 months. 10 pts
received Donor Leukocyte Infusion of 1 to 7 doses. 4 of the 10
patients had remarkable disease response after DLI (2 converted to
CR, 1 PR going into CR, 1 stable). 10/18 pts had acute GVHD
(grade II-IV), 4 of them developed GVHD after DLI. Day 100
mortality is 5% (1/18). With a median follow-up of 28 months
(1-38), the median duration of overall survival (OS) for these
high-risk patients has not been reached. 1 year OS is 64%, 2 year
OS is 52%. For the 14 pts who failed prior Auto-SCT, 1 year OS
is 69%, 2 year OS is 52%. These data are highly suggestive of
graft-vs-lymphoma effect. Therefore, mini-allogeneic transplanta-
tion after MAP is a favorable option for lymphoma patients, par-
ticularly for those who failed prior Auto-SCT.
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TID COMPARED TO BID MYCOPHENOLATE MOFETIL (MMF) IMPROVES
DONOR CHIMERISM AND ENGRAFTMENT RATES WITHOUT INCREAS-
ING POSTGRAFTING TOXICITIES AFTER UNRELATED PERIPHERAL
BLOOD STEM CELL (PBSC) TRANSPLANTATION (HCT) WITH NONMY-
ELOABLATIVE CONDITIONING
Maris, M.B.1,2, Sandmaier, B.M.1,2, Storer, B.1,2, Stuart, M.3, Agura,
E.4, Hegenbart, U.5, Pulsipher, M.6, Maziarz, R.T.7, Bruno, B.8,
McSweeney, P.9, Maloney, D.1,2, Niederwieser, D.5, Blume, K.3, Storb,
R.1,2 1. Fred Hutchinson Cancer Research Center; 2. University of
Washington; 3. Stanford University; 4. Baylor University, Dallas; 5.
University of Leipzig, Germany; 6. Oregon Health and Sciences Uni-
versity; 7. University of Turin, Italy; 8. University of Colorado.
Poster Session I
35BB&MT
